|
Continual dystonia
|
Continual_dystonia |
|
|
Peak dose dyskinesia
|
Peak_dose_dyskinesia |
|
|
Drug-induced dyskinesia
|
Drug-induced_dyskinesia |
|
|
Haloperidol-induced parkinsonism
|
Haloperidol-induced_parkinsonism |
|
|
Drug induced parkinsonism
|
Drug-induced_parkinsonism |
|
|
Hydrocephalus
|
Hydrocephalus |
|
|
Secondary parkinsonism
|
Secondary_parkinsonism |
|
|
Olfactory dysfunction
|
Olfactory_dysfunction |
|
|
OMICS biomarkers of Parkinson disease
|
OMICS_biomarkers_of_Parkinson_disease |
|
|
SH SY5Y
|
SH-SY5Y |
|
|
Dopaminergic cell line
|
Dopaminergic_cell_lines |
|
|
Bradykinesia
|
Bradykinesia_symptom |
|
|
Motor symptom
|
Motor_features |
|
|
Neurorestorative treatment
|
Neurorestorative_treatment |
|
|
Treatment of Parkinson's disease
|
Treatment_of_Parkinson_s_disease |
|
|
Dopamine dysregulation syndrome
|
Dopamine_dysregulation_syndrome |
|
|
Long term complication of medication
|
Long_term_complication_of_medication |
|
|
Parkinsons disease cognitive rating scale
|
Parkinsons_disease_cognitive_rating_scale |
|
|
Clinical rating scale
|
Clinical_rating_scale |
|
|
Hypnogenic dyskinesia
|
Hypnogenic_dyskinesia |
|
